Department of Gastroenterology, The First Affiliated Hospital of Nanchang University and China Jiangxi Clinical Research Center for Gastroenterology, Nanchang, Jiangxi 330006, China.
Department of Gastroenterology, The First Affiliated Hospital of Nanchang University and China Jiangxi Clinical Research Center for Gastroenterology, Nanchang, Jiangxi 330006, China.
Dig Liver Dis. 2022 Oct;54(10):1358-1366. doi: 10.1016/j.dld.2022.04.007. Epub 2022 Apr 30.
Previous studies suggested miR-21 regulated epithelial-mesenchymal transition (EMT) and fibrosis in organs. The aim of this study was to explore the role and mechanism of miR-21 in EMT process of CD(Crohn's disease)-associated intestinal fibrosis.
Tissue biopsies from fibrotic and nonfibrotic intestine of CD patients, and non-CD patients were obtained; chronic intestinal fibrosis model established by TNBS was treated with antagonist of miR-21; human intestinal epithelial cell, NCM460, were transfected with miR-21 mimics or inhibitor. The expressions of PTEN and mTOR, EMT-related markers and severity of colitis and fibrosis were examined.
Compared to the controls, miR-21 was significantly upregulated in the intestinal tissues from CD patients with fibro stenosis, followed by decreased PTEN expression, increased EMT markers, and mTOR expression, and imbalanced ratio of MMP9(matrix metalloproteinase 9)/TIMP1(tissue inhibitor of metalloproteinase 1). MiR-21 downregulated the expression of PTEN and upregulated mTOR signal in NCM460 cell. Also, knocking miR-21 down reduced EMT in vitro. Inhibiting miR-21 with antagonists reversed TNBS-induced intestinal fibrosis in vivo, through suppressing EMT and balancing MMPs/TIMPs.
We identified the involvement of miR-21 in EMT during intestinal fibrosis via targeting PTEN and mTOR, and miR-21 inhibition relieved intestinal fibrosis by regulating extracellular matrix (ECM) remodeling . Our results indicated miR-21 as a potential new target for the treatment of fibrosis complication in CD.
先前的研究表明 miR-21 调节器官中的上皮间质转化 (EMT) 和纤维化。本研究旨在探讨 miR-21 在 CD(克罗恩病)相关肠道纤维化 EMT 过程中的作用和机制。
从 CD 患者的纤维化和非纤维化肠道以及非 CD 患者中获取组织活检;用 miR-21 拮抗剂处理 TNBS 诱导的慢性肠道纤维化模型;用 miR-21 模拟物或抑制剂转染人肠上皮细胞 NCM460。检测 PTEN 和 mTOR、EMT 相关标志物以及结肠炎和纤维化的严重程度。
与对照组相比,miR-21 在 CD 伴有纤维狭窄的患者肠道组织中显著上调,随后 PTEN 表达降低,EMT 标志物增加,mTOR 表达增加,MMP9(基质金属蛋白酶 9)/TIMP1(金属蛋白酶组织抑制剂 1)的平衡比值失调。miR-21 在 NCM460 细胞中下调 PTEN 的表达并上调 mTOR 信号。此外,敲低 miR-21 可减少体外 EMT。用拮抗剂抑制 miR-21 可通过抑制 EMT 和平衡 MMPs/TIMPs 逆转体内 TNBS 诱导的肠道纤维化。
我们通过靶向 PTEN 和 mTOR 鉴定了 miR-21 在肠道纤维化过程中的 EMT 参与,并且通过调节细胞外基质 (ECM) 重塑抑制 miR-21 缓解了肠道纤维化。我们的研究结果表明 miR-21 是 CD 纤维化并发症治疗的潜在新靶点。